Related Experiment Videos
Clinical multicentre trial with josamycin propionate in paediatric patients
Insights
Josamycin propionate is a highly effective antibiotic for treating pediatric infections, demonstrating a 97.1% success rate. This tasteless oral suspension was well-tolerated by children, with a low incidence of side effects.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
Background:
- Josamycin propionate, a tasteless derivative of josamycin, is formulated for pediatric oral suspensions.
- Evaluating new antibiotic formulations is crucial for improving pediatric treatment adherence and outcomes.
Purpose of the Study:
- To assess the clinical effectiveness and safety of josamycin propionate in pediatric patients.
- To determine the tolerability and acceptance of josamycin propionate in children.
Main Methods:
- A large, multicenter clinical study involving 1908 children treated by 200 pediatric practitioners.
- Dosage: mean daily dose of 53.5 mg/kg for an average of 7.31 days.
- Infections treated primarily included respiratory and pararespiratory conditions.
Main Results:
- Josamycin propionate achieved a high success rate of 97.1% in treating pediatric infections.
- The drug was well-tolerated, with only 5.14% of patients experiencing side effects.
- Attributable side effects in a subgroup of 300 patients not on other drugs occurred at a rate of 3.33%.
Conclusions:
- Josamycin propionate is a highly effective and well-tolerated antimicrobial agent for pediatric practice.
- The formulation's palatability enhances patient acceptance, crucial for effective antibiotic therapy in children.
- The study supports the use of josamycin propionate for common pediatric infections.
Abstract:
Josamycin propionate, a tasteless josamycin derivative suitable for the preparation of paediatric oral suspension, was employed in a large, multicentre clinical study aimed at evaluating the effectiveness and safety of the drug. Two hundred paediatric practitioners participated in the study, and 1908 children (mean age 5.27 years) were treated. Respiratory and pararespiratory infections were the most common diagnosis. The mean daily dose of josamycin was 53.5 mg/kg and the drug was administered for an average of 7.31 days. Josamycin proved to be a highly effective antimicrobial agent for the treatment of infections occurring in paediatric practice, with a success rate of 97.1%. The drug also showed a high degree of acceptance by the young patients and was very well tolerated: only 98 children (5.14%) developed side-effects during the treatment. However, the side-effects observed were reliably attributable to josamycin in only 10 out of 300 subjects who were not receiving other drugs; among these the frequency rate was 3.33%.